

WHO Drug Information

Contents

General Policy Topics

- Trademarks versus generic names for pharmaceuticals 39

Points of view

- New trends in drug evaluation in Italy 41

Reports on Individual Drugs

- Ivermectin in onchocerciasis 43

General Information

- Continuous cell lines in the production of biologicals 46
 Focus on interferons 46
 Community pharmaceutical services in Nigeria: towards self-reliance 47
 Drugs and alternative medicine 47
 Herbal medicines: safe and effective? 48
 Continuous subcutaneous insulin infusion 48
 A new focus on pharmaceuticals 49
 New recommended schedule for active immunization of infants and children 49
 Immunization programmes: inappropriate application of contraindications 50
 Transmission of hepatitis B with jet gun injections 50
 Screening for non-A, non-B hepatitis 50
 The evaluation of teratogenicity of chemical substances 51
 Definition of a teratogen 51
 Fetal abnormalities and use of drugs during pregnancy 52
 Reporting congenital malformations 52
 Post-marketing surveillance and medical databases 52
 3rd International Conference on Pharmacoepidemiology 53
 Drug abuse in the Americas and the Caribbean 53
 Draft guidelines for the investigation of bioavailability 54
 Research on healthy volunteers 55

- Pharmacovigilance: a decentralized system 55
 Pharmacopoeias, compendia and texts of GMPs 55
 Chemical analysis unnecessary for most drugs 55
 Pharmacists' role in infection control 55
 Research on new drugs involving human subjects 56
 Bleeding and antibiotic treatment 56
 Blood disorders associated with pirenzepine 56
 Intravaginal dinoprostone for induction of labour at term 56
 Tardive dyskinesia in antipsychotic therapy 57
 Ibuprofen and aspirin safe in over-the-counter use 57
 "Congesting" nasal decongestants 57
 Electrical stimulation devices to treat scoliosis 58
 Sugar in oral liquid medicines 58
 Drug interference in thyroid testing 58
 Cardiac pacemaker registry 58
 Oxybutynin prescribing "unusually high" 58
 Benzodiazepine dependence 59
 Amitriptyline in diabetic neuropathy 60
 A review of clinical risks 60
 Barbiturate anaesthetics and termination of pregnancy 60
 Nifedipine, a new calcium antagonist 60
 Biotechnology patents for pharmaceuticals 60
 Standardization of rabies immunoglobulin 61
 World Federation of Associations of Clinical Toxicology Centres and Poison Control Centres 61

Update on AIDS

- Prospects for vaccines and antiviral therapy 62
 Zidovudine 72
 Keeping the AIDS virus out of blood supplies 65
 AIDS: condoms on prescription? 65
 Safety of factor VIII and IX concentrates 65
 Autologous blood transfusion 65
 Zidovudine available under AIDS treatment research protocol 66
 AIDS, condoms and spermicides 66

(continued)

Contents (continued)

Pharmaceutical Products Approved		Advisory Notices	
Benzodiazepine antagonist	67	Pregnancy warnings in data sheets	80
Diagnostic assay for hepatitis delta agent	67	Clinical evaluation of non-steroidal anti-inflammatory drugs	80
Biotechnology: a new hepatitis B vaccine	67	Allergen extracts and anaphylaxis	80
Other products approved	68	Adverse effects of anti-infective drugs	81
		Anabolic steroids and athletic performance	82
Reports from Regulatory Agencies		Essential Drugs	
Aminophenazone, Anticholinergic drugs, Barbiturates, Bepridil, Bucetin, Bupivacaine	69	"River blindness" affects 18 million people	83
Captopril, Carbamazepine, Flunitrazepam		Diethylcarbamazine	83
Hydrocortisone (topical preparations), Mefloquine	70	Suramin sodium	85
Mianserin, Metformin, Nifedipine		Accelerated stability studies under simulated tropical conditions	86
Paracetamol	71	Sensitivity of <i>Plasmodium falciparum</i> to quinine and mefloquine in Thailand	87
Phenacetin, Spironolactone, Sulpiride, Tartrazine, Other decisions	72	Nigeria adopts an essential drugs list	87
		Sudan's new drug policy and essential drugs list	88
Regulatory Matters		Recent Publications	
The future of regulatory affairs in Europe	73	Essential malariology	89
Pharmaceuticals in the European Community	73	Treatment of cardiac tachyarrhythmias	89
Controlled studies not essential for "home medicines"	74	Medicinal products for use in self-medication	89
Exports of unapproved drugs: new legislation	74	Drugs in hospitals	90
Carcinogenicity studies	75	Pharmaceutical regulation in Italy	90
Mutual recognition of toxicological data	76	A handbook of pharmaceutical excipients	90
Good Laboratory Practices	76	Drug information for the health care provider	90
Proprietary medicinal products—Nordic guidelines for evaluation reports	76	Pharmaceutical administration in Japan	90
Over-the-counter drug (OTC) review	76	Treatment of sexually transmitted disease	91
Good Manufacturing Practices for medical devices	77	Cancer pain relief	91
Sterility testing of parenteral drugs	77	Human experimentation: legal and ethical aspects	91
Mutual recognition of inspection certificates	77	Drug consumption in Norway	91
Approved veterinary drugs	77	Drug information bulletin from Chile	92
Labelling and advertising of new animal drugs	78	A magazine from the German Democratic Republic	92
Generic drugs for animals	78	An international society of editors of drug bulletins	92
Product liability and its implications for the practice of pharmacy and medicine	78		
Drug Regulatory Index	79	Proposed International Nonproprietary Names: List 57	93